Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

April 26, 2013

Study Completion Date

February 13, 2017

Conditions
Lymphoma, Hodgkin DiseaseLymphomaHodgkin DiseaseLymphoma: Hodgkin
Interventions
DRUG

Vincristine

1.4 mg/m² intravenously (IV) on week 2, 4, 6, 8

DRUG

Cyclophosphamide

650 mg/m², on week 1 and 5

DRUG

Doxorubicin

25 mg/m², on week 1, 3, 5, 7

DRUG

Prednisone

40 mg/m², oral, every other day. Taper-reduction 10 mg/m² every other day during last 2 weeks of chemotherapy

DRUG

Bleomycin

5 u/m² intravenously (IV) on week 2, 4, 6, 8

DRUG

Etoposide

60 mg/m² x 2 intravenously (IV) on week 3, 7 (d 15, 16, 43, 44)

RADIATION

Low-dose radiotherapy (RT)

20 Grey (Gy) modified involved field radiotherapy administered as consolidative irradiation will beginning between 2 and 12 weeks after the completion of Stanford V-C chemotherapy regimen.

Trial Locations (2)

94305

Stanford University School of Medicine, Stanford

94589

Kaiser Permanente Medical Center, Vallejo

All Listed Sponsors
lead

Stanford University

OTHER

NCT00026208 - Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter